CN106176830A - 灰树花提取物及其制备方法和应用 - Google Patents
灰树花提取物及其制备方法和应用 Download PDFInfo
- Publication number
- CN106176830A CN106176830A CN201610711121.6A CN201610711121A CN106176830A CN 106176830 A CN106176830 A CN 106176830A CN 201610711121 A CN201610711121 A CN 201610711121A CN 106176830 A CN106176830 A CN 106176830A
- Authority
- CN
- China
- Prior art keywords
- grifola frondosa
- extracts
- active
- effects
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000001080 Grifola frondosa Species 0.000 title claims abstract description 63
- 235000007710 Grifola frondosa Nutrition 0.000 title claims abstract description 63
- 239000000284 extract Substances 0.000 title claims abstract description 40
- 230000000694 effects Effects 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 28
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229940116269 uric acid Drugs 0.000 claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 241000283707 Capra Species 0.000 claims abstract description 7
- 201000005569 Gout Diseases 0.000 claims abstract description 7
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 11
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims description 11
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 11
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims description 11
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 238000004821 distillation Methods 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 230000006837 decompression Effects 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 4
- 206010061623 Adverse drug reaction Diseases 0.000 abstract description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000003960 organic solvent Substances 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000002481 ethanol extraction Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- 206010003246 arthritis Diseases 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 201000001431 Hyperuricemia Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 4
- 229960003459 allopurinol Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- -1 ucleosides Chemical class 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000207961 Sesamum Species 0.000 description 2
- 235000003434 Sesamum indicum Nutrition 0.000 description 2
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000010977 jade Substances 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- 241000222382 Agaricomycotina Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000380450 Danaus melanippus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241000222383 Polyporales Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种灰树花提取物及其制备方法和应用,其中,制备方法使用资源丰富、价格便宜、环境友好的乙醇、水或者乙醇和水混合物作为溶剂,达到降低生产成本、避免有机溶剂污染的目的。体内实验表明,本发明制得的灰树花提取物具有显著的降尿酸作用,能够用于制备缓解痛风病症的药物,为改善目前痛风病药物副作用大的现象提供了新的方向。
Description
【技术领域】
本发明涉及一种灰树花提取物、制备方法及其应用,属于保健品和中药领域。
【背景技术】
痛风病严重困扰人类生活,新西兰、美国和中国的流行病学研究表明痛风病症变得越来越普遍,发病率约为2%,并不断升高。其中65岁及以上人群发生率最高,男性的发病率比女性发病率两倍还高。痛风病是高尿酸血症发展的结果,是由于体内尿酸浓度高于血液溶解能力(>360μmol/L),导致尿酸钠晶体在软组织、关节沉积,这些沉积结晶引起软组织、关节和骨组织反复发炎性剧烈疼痛,严重降低患者生活质量。
痛风病分为急性和慢性两种。目前市场上针对急性痛风病治疗药物包括非甾体抗炎药、秋水仙素、促肾上腺皮质激素或类固醇,这些药物主要是作用于炎症因子,降低患者痛苦。对于慢性痛风病,管理血液尿酸水平是关键。目前,用来降低人体内尿酸浓度的药物主要有:别嘌呤醇、促尿酸排泄药物以及利尿药物,包括苯溴马隆、尿酸酶、PEG改性的尿酸酶等,这些药物因为对肝和肾代谢器官有较强副作用使得患有肝病和肾病的患者不能使用,同时这些药物容易引发胃肠道和心血管病。这使得患有高血压、充血性心力衰竭、胃炎/溃疡或者肾功能不全的痛风患者服用上述药物通常具有较高危险性。中药疗效好、副作用低,其优势逐渐显现,因而在临床上广泛使用。因此,寻找具有降尿酸作用的中药具有重要意义。
在我国民间,灰树花有着悠久的采食历史。公元二世纪的《太上灵宝芝草品》中配图并记载灰树花为:白玉芝,称:“白玉芝生于方丈山中,其味辛,白盖四重,下一重上有二枚生,并有3枚生上重,或生大石之上,黄沙之中,腐木之根,高树之下,名山之阴,得而食之,仙矣。白虎守之。”我国宋代的陈仁玉在《菌谱》也有记述灰树花为食用菌,“味甘、平、无毒,可治痔疮”。
灰树花隶属于担子菌亚门,层菌纲,无革担子菌亚纲,非褶菌目,多孔菌科,树花属。性甘、味平,具有益气健脾,补虚扶正的功效,主治脾虚气弱、体倦乏力、神疲懒言、饮食减少、肿瘤患者放疗或化疗后有上述症状者,但是目前尚无灰树花针对治疗高尿酸血症、痛风病症的相关报道。
【发明内容】
针对上述现有技术,本发明的在于提供一种灰树花提取物及其制备方法和应用,其中,制备方法使用资源丰富、价格便宜、环境友好的乙醇、水或者乙醇和水混合物作为溶剂,达到降低生产成本、避免有机溶剂污染的目的。具体包括以下步骤:
(1)将干燥的灰树花子实体粉碎;
(2)将粉碎后的灰树花子实体置于5-25倍重量的乙醇、水或者乙醇和水混合溶剂中,在40-100℃下提取2-6小时,用400目滤网过滤,分别收集滤液和滤渣;
(3)用与步骤(2)相同的条件重复提取所得滤渣中的营养物质。
(4)将步骤(2)和(3)所得的滤液合并后减压蒸馏浓缩至25-35mL;
(5)将步骤(4)所得的浓缩液冻干得到灰树花提取物。
优选的,上述步骤(2)中的提取过程为超声提取,温度最好为60℃,时间为3小时。
按照上述方法制得的灰树花提取物,含有粗蛋白、粗脂肪、多糖、甘露醇、海藻糖、苹果酸、麦角甾醇、肽类、甾醇类、核苷类、氨基酸、有机酸、维生素及无机元素,其中,麦角甾醇含量为0.17-0.29%,多糖含量为8-35%,蛋白含量为17-35%。
利用方法制得的灰树花提取物进行小鼠体内降尿酸试验,结果表明用灰树花提取物连续灌胃7天,可将高尿酸小鼠的血液尿酸浓度降低到低于正常小鼠尿酸水平。
因此,本发明的另一目的是提供一种灰树花提取物在制备降低血液尿酸水平、改善高尿酸血症、改善痛风病症的药物、保健品或辅助药剂中的应用。
本发明的另一目的是提供一种治疗痛风病的药物,其特征在于,该药物中含有灰树花提取物。
本发明的有益效果在于:
1、本发明所述灰树花提取物的制备工艺简单,成本低;
2、本发明采用乙醇、水或者乙醇和水的混合溶剂作为溶剂提取灰树花,不存在有机溶剂污染或残留的问题,安全环保;
3、本发明灰树花提取物具有显著的降尿酸作用,能够用于制备缓解痛风病症的药物,为改善目前痛风病药物副作用大的现象提供了新的方向。
【附图说明】
图1:各组小鼠血清中尿酸浓度
【具体实施方式】
以下结合实施例来进一步解释本发明,但实施例并不对本发明做任何形式的限定。
实施例1
(1)、灰树花乙醇提取物的制备
取灰树花子实体100g,使用粉碎机粉碎后加入锥形瓶中,并加入1L乙醇,将混合物在60℃下水浴提取3小时后使用400目滤网过滤。提取实验重复一次,将所得滤液合并后减压蒸馏浓缩至25mL,冻干得到灰树花乙醇提取物5.22g,产率为5.22%。
(2)、灰树花提取物中各组分含量测定
多糖测定:采用硫酸-苯酚法测得上述灰树花乙醇提取物中多糖含量为8%。
蛋白测定:使用考马斯亮蓝染色法(Bradford法)测得上述灰树花乙醇提取物中蛋白含量为17%。
麦角甾醇测定:采用HPLC法测定麦角甾醇含量,其中,甲醇为流动相,流速为1.3mL/min,检测波长为282nm,柱温为29℃,测得上述灰树花乙醇提取物中麦角甾醇含量为0.29%。
实施例2
(1)、灰树花水提取物的制备
取灰树花子实体100g,使用粉碎机粉碎后加入锥形瓶中,并加入1.5L乙醇,将混合物在95℃下水浴提取4小时后使用400目滤网过滤。提取实验重复一次,将所得滤液合并后减压蒸馏浓缩至300mL,冻干得到灰树花乙醇提取物5.60g,产率为5.60%。
(2)、灰树花提取物中各组分含量测定
多糖测定:采用硫酸-苯酚法测得上述灰树花水提取物中多糖含量为27%。
蛋白测定:使用考马斯亮蓝染色法(Bradford法)测得上述灰树花水提取物中蛋白含量为31%。
麦角甾醇测定:采用HPLC法测定麦角甾醇含量,其中,甲醇为流动相,流速为1.3mL/min,检测波长为282nm,柱温为29℃,测得上述灰树花乙醇提取物中麦角甾醇含量为0.17%。
实施例3
取灰树花子实体100g,使用粉碎机粉碎后加入锥形瓶中,并加入500mL蒸馏水,将混合物在100℃下煎煮提取2小时后使用400目滤网过滤。提取实验重复一次,将所得滤液合并后减压蒸馏浓缩至35mL,冻干得到灰树花水提取物9.5g,产率为9.5%。
经检测,本实施例得到的灰树花提取物中,多糖含量为21%、蛋白质含量为23%、麦角甾醇含量为0.18%,其检测方法同实施例1。
实施例4
取灰树花子实体100g,使用粉碎机粉碎后加入锥形瓶中,并加入2.5L蒸馏水,将混合物在60℃下超声提取6小时后使用400目滤网过滤。提取实验重复一次,将所得滤液合并后减压蒸馏浓缩至25mL,冻干得到灰树花水提取物10.5g,产率为10.5%。
经检测,本实施例得到的灰树花提取物中,多糖含量为35%、蛋白质含量为35%、麦角甾醇含量为0.26%,其检测方法同实施例1。
实施例5
取灰树花子实体100g,使用粉碎机粉碎后加入锥形瓶中,并加入2.0L蒸馏水,将混合物在90℃下水浴提取5小时后使用400目滤网过滤。提取实验重复一次,将所得滤液合并后减压蒸馏浓缩至30mL,冻干得到灰树花水提取物8.7g,产率为8.7%。
经检测,本实施例得到的灰树花提取物中,多糖含量为27%、蛋白质含量为24%、麦角甾醇含量为0.20%,其检测方法同实施例1。
四、灰树花提取物降尿酸实验
取50只雄性SPF昆明小鼠(20±2g),随机分为5组:正常对照组、高尿酸血症模型对照组、阳性对照组、实验组1、实验组2。除正常对照组腹腔注射和灌胃纯水外,其他组按照100mg/kg/d的剂量腹腔注射氧嗪酸钾盐,同时灌胃600mg/kg/d剂量的次黄嘌呤造模。造模前一个小时禁食不禁水,造模后1小时,阳性对照组灌胃5mg/kg/d剂量的别嘌呤醇(AL),实验组1灌胃100mg/kg/d剂量的实施例1制得的灰树花乙醇提取物,实验组2灌胃100mg/kg/d剂量的实施例4制得的灰树花水提取物,正常对照组和高尿酸血症模型对照组则灌胃相同体积的纯水,连续7天。第7天灌胃给药1小时后,麻醉摘眼球取血,使用离心机在3500r/min速度下离心10min分离得到血清,检测血清中尿酸浓度。
结果如图1所示(*和**表示与正常对照组相比,差异显著分别为P<0.05和P<0.01;#和##表示与模型对照组相比,差异显著分别为P<0.05和P<0.01;Δ和ΔΔ表示与阳性对照组相比,差异显著分别为P<0.05和P<0.01)。
由图1可知,与正常对照组相比,模型对照组血清尿酸水平达到386.8μmol/L,高于正常对照组326.1μmol/L,差异显著性为P<0.05,这表明高尿酸血症小鼠模型造模成功。与模型组相比,阳性对照药别嘌呤醇成功地使高尿酸小鼠血清尿酸水平从386.8μmol/L降到230.6μmol/L,差异显著性为P<0.01,这进一步说明高尿酸血症小鼠模型造模成功。实施例1制得的灰树花乙醇提取物使高尿酸小鼠血清尿酸水平从386.8μmol/L降为206.3μmol/L,这与模型对照组相比差异显著性为P<0.01,成功地降低了高尿酸小鼠的血清尿酸水平。实施例4制得的灰树花水提取物使高尿酸小鼠血清尿酸水平从386.8μmol/L降为152.5μmol/L,这与模型对照组相比差异显著性为P<0.01,成功地降低了高尿酸小鼠的血清尿酸水平。
上述结果说明,本发明灰树花提取物具有良好的降尿酸效果,其降尿酸效果可以使高尿酸模型组血液尿酸浓度降至低于正常小鼠尿酸水平。另外,灰树花作为药食同源的真菌,对人身体无损伤,它的提取物可以用于制备降尿酸、改善痛风的药物、保健品或辅助药剂中。
Claims (7)
1.灰树花提取物的制备方法,其特征在于,包括以下步骤:
(1)将干燥的灰树花子实体粉碎;
(2)将粉碎后的灰树花子实体置于5-25倍重量的乙醇、水或者乙醇和水混合溶剂中,在40-100℃下提取2-6小时,用400目滤网过滤,分别收集滤液和滤渣;
(3)用与步骤(2)相同的条件重复提取所得滤渣中的营养物质。
(4)将步骤(2)和(3)所得的滤液合并后减压蒸馏浓缩至25-35mL;
(5)将步骤(4)所得的浓缩液冻干得到灰树花提取物。
2.根据权利要求1所述的灰树花提取物的制备方法,其特征在于,所述步骤(2)中的提取温度为60℃。
3.根据权利要求1所述的灰树花提取物的制备方法,其特征在于,所述步骤(2)中的提取过程为超声提取。
4.根据权利要求1-3中任一项所述的灰树花提取物制备方法制得的灰树花提取物。
5.根据权利要求4所述的灰树花提取物,其特征在于,所述灰树花提取物中,麦角甾醇含量为0.17-0.29%,多糖含量为8-35%,蛋白含量为17-35%。
6.权利要求3或4所述的灰树花提取物在制备降低尿酸浓度、改善痛风病症的药物、保健品或辅助药剂中的应用。
7.一种治疗痛风病的药物,其特征在于,所述药物含有权利要求3或4所述的灰树花提取物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610711121.6A CN106176830A (zh) | 2016-08-24 | 2016-08-24 | 灰树花提取物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610711121.6A CN106176830A (zh) | 2016-08-24 | 2016-08-24 | 灰树花提取物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106176830A true CN106176830A (zh) | 2016-12-07 |
Family
ID=57524084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610711121.6A Pending CN106176830A (zh) | 2016-08-24 | 2016-08-24 | 灰树花提取物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106176830A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106692158A (zh) * | 2017-01-18 | 2017-05-24 | 广东省微生物研究所 | 维生素b1、虫草酸、核黄素及其组合物在降尿酸药物中的应用 |
CN107648283A (zh) * | 2017-09-28 | 2018-02-02 | 北京市农林科学院 | 保护受损肝细胞的产品及其应用 |
WO2019218507A1 (zh) * | 2018-05-14 | 2019-11-21 | 广东省微生物研究所(广东省微生物分析检测中心) | 茶树菇提取物的制备方法及其在制备降尿酸药物的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010030949A (ja) * | 2008-07-29 | 2010-02-12 | Tsujido Chemical Corp | 高尿酸血症の予防または改善剤 |
-
2016
- 2016-08-24 CN CN201610711121.6A patent/CN106176830A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010030949A (ja) * | 2008-07-29 | 2010-02-12 | Tsujido Chemical Corp | 高尿酸血症の予防または改善剤 |
Non-Patent Citations (2)
Title |
---|
周昌艳等: "灰树花提取物清除氧自由基的研究", 《菌物研究》 * |
张士国等: "灰树花子实体多糖提取方法的比较", 《中国林副特产》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106692158A (zh) * | 2017-01-18 | 2017-05-24 | 广东省微生物研究所 | 维生素b1、虫草酸、核黄素及其组合物在降尿酸药物中的应用 |
CN107648283A (zh) * | 2017-09-28 | 2018-02-02 | 北京市农林科学院 | 保护受损肝细胞的产品及其应用 |
CN107648283B (zh) * | 2017-09-28 | 2020-07-24 | 北京市农林科学院 | 保护受损肝细胞的产品及其应用 |
WO2019218507A1 (zh) * | 2018-05-14 | 2019-11-21 | 广东省微生物研究所(广东省微生物分析检测中心) | 茶树菇提取物的制备方法及其在制备降尿酸药物的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104473977B (zh) | 一种蛹虫草水提物、制备方法及其应用 | |
CN101874857B (zh) | 抗酒精性肝损伤的护肝白酒及其生产工艺 | |
CN107581619A (zh) | 一种抗疲劳抗衰老海参牡蛎肽复合胶囊及其制备方法 | |
CN104263790B (zh) | 一种肉苁蓉多肽提取物、制备方法及其用途 | |
CN106176830A (zh) | 灰树花提取物及其制备方法和应用 | |
CN102271698A (zh) | 药物组合物及其在制备药剂中的用途 | |
JP6605036B2 (ja) | 肝臓及び腎臓の損傷関連疾患を予防し又は治療する中医薬組成物の調製法 | |
CN101664180B (zh) | 一种具有保健功效的营养复合剂及其制备方法 | |
CN104126707A (zh) | 一种调理动脉粥样硬化的茶 | |
CN106038672A (zh) | 美藤果壳提取物在制备降压药物中的应用 | |
CN104336593A (zh) | 一种参茸石斛保健食品及其制备方法 | |
CN103229872B (zh) | 一种延缓衰老的食品养生茶冲剂 | |
CN104998252A (zh) | 一种补铁补血口服液及其制备方法 | |
CN104721467B (zh) | 一种治疗糖尿病肾病的中药组合物及其用途 | |
CN105999217A (zh) | 一种防治高尿酸的组合物及其制备方法和应用 | |
JP2016529261A (ja) | 血清高密度リポタンパク質(hdl)濃度を著しく増加させる漢方薬複合組成物及び製造方法 | |
CN106581166A (zh) | 一种具有抗疲劳功效的食品、保健品或药物组合物 | |
CN108741056A (zh) | 一种调节免疫功能的爬沙虫提取物的制备方法 | |
CN111419999B (zh) | 治疗高尿酸血症的中药组合物及其制备方法 | |
CN104546986A (zh) | 一种治疗慢性缺氧性肺系疾病的中药组合物及其制备方法 | |
CN107669711A (zh) | 树舌提取物的制备方法及其用途 | |
CN107468899A (zh) | 一种补血丸及其制备方法 | |
CN107805577A (zh) | 一种金线莲养生酒的制备方法 | |
CN103860628A (zh) | 一种解酒醒酒中成药制剂及其制备方法 | |
CN103251876A (zh) | 一种治疗慢性肝病的中药组合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161207 |